FDA Approves First New ALS Drug Since 1995

May 08, 2017

The U.S. FDA has approved the first new drug for amyotrophic lateral sclerosis (ALS) in 22 years.

NJ-based Mitsubishi Tanabe Pharma's infusion therapy, Radicava, is just the second treatment for ALS approved in the United States. Sanofi's Rilutek was approved in 1995, and generic versions became available in 2013.

 MT Pharma submitted Radicava for U.S. approval with encouragement from U.S. regulators, following promising late-stage trial results in Japan.

Mitsubishi Tanabe is reportedly seeking a list price of $1,000 per infusion of the drug, which has to be administered by a health care professional via IV. 

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments